Molecularly targeted therapies in unresectable-metastatic gastric cancer. A systematic review

Cancer Treatment Reviews

Volumn 37, Issue 8, 2011, Pages 599-610

  Zagouri, Flora ^a   Papadimitriou, Christos A ^a   Dimopoulos, Meletios Athanassios ^a   Pectasides, Dimitrios ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Gastric cancer; Molecularly targeted agents; Target therapy

Indexed keywords

BEVACIZUMAB; BORTEZOMIB; BRYOSTATIN 1; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIRUBICIN; ERLOTINIB; EVEROLIMUS; FLAVOPIRIDOL; FLUOROURACIL; FOLINIC ACID; FORETINIB; GEFITINIB; IRINOTECAN; LAPATINIB; MARIMASTAT; MATUZUMAB; MITOMYCIN; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; SORAFENIB; SUNITINIB; TRASTUZUMAB;

ABDOMINAL PAIN; ACNE; ANEMIA; ANOREXIA; ARTERY THROMBOSIS; ASTHENIA; BLEEDING; BRAIN ISCHEMIA; CANCER COMBINATION CHEMOTHERAPY; COLORECTAL CANCER; DEHYDRATION; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DYSPNEA; ESOPHAGUS CANCER; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL HEMORRHAGE; HAND FOOT SYNDROME; HEART ARREST; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; HYPONATREMIA; INFECTION; INFLAMMATION; INOPERABLE CANCER; LETHARGY; LEUKOPENIA; LIVER TOXICITY; LUNG EMBOLISM; LYMPHOCYTOPENIA; METASTASIS; MOLECULARLY TARGETED THERAPY; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA; NEUTROPENIA; PARONYCHIA; PERIPHERAL NEUROPATHY; PLEURA EFFUSION; PNEUMONIA; RASH; REVIEW; SENSORY NEUROPATHY; SIDE EFFECT; SKIN DISEASE; SKIN MANIFESTATION; SKIN TOXICITY; STOMACH CANCER; STOMACH CARCINOGENESIS; STOMACH PERFORATION; STOMATITIS; SYNCOPE; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; VOMITING; WOUND HEALING IMPAIRMENT;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; REVIEW LITERATURE AS TOPIC; STOMACH NEOPLASMS;

EID: 80054071524     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2011.03.007     Document Type: Review

References (116)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics. CA Cancer J Clin 2008, 58:71-96.
2. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
3. Parkin D.M., Pisani P., Ferlay J. Global cancer statistics. CA Cancer J Clin 1999, 49:33-64.
4. Cunningham D., Starling N., Rao S., et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008, 358:36-46.
5. Liberati A., Altman D.G., Tetzlaff J., et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 2009, 62:e1-34.
6. Kang Y., Ohtsu A., van Cutsem E., et al. AVAGAST: A randomized double-blind, placebo-controlled, phase III study of first-line capecitabine/cisplatin + bevacizumab or placebo in patients with advanced gastric cancer (AGC). J Clin Oncol 2010, 28:7s. [Abstract].
7. Shah M, Kang Y, Ohtsu A, et al. Tumor and blood biomarker analyses in the AVAGAST phase III randomized study of first-line bevacizumab + capecitabine/cisplatin in patients with advanced gastric cancer. 35th ESMO Congress 2010. [Abstract].
8. Shah M.A., Ramanathan R.K., Ilson D.H., et al. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 2006, 24:5201-5206.
9. Enzinger P, Fidias P, Meyerhardt J, et al. Phase II study of bevacizumab and docetaxel in metastatic esophageal and gastric cancer. In: Proc GI ASCO 2006, vol. 68 [abstract].
10. Peinert S., Arnold D., Siewczynski R., et al. BECAM: a salvage protocol with bevacizumab, capecitabine, mitomycin C for patients with refractory metastatic colorectal cancer (CRC) or gastric cancer (GC). J Clin Oncol 2006, 24:13554. [abstract].
11. Kelsen D., Jhawer M., Ilson D., et al. Analysis of survival with modified docetaxel, cisplatin, fluorouracil (mDCF), bevacizumab (BEV) in patients with metastatic gastroesophageal (GE) adenocarcinoma: results of a phase II clinical trial. J Clin Oncol 2009, 27:4512. [abstract].
12. Enzinger P., Ryan D., Regan E., et al. Phase II trial of docetaxel, cisplatin, irinotecan, bevacizumab in metastatic esophagogastric cancer. J Clin Oncol 2008, 26:4552. [abstract].
13. El-Rayes BF, Zalupski M, Bekai-Saab T, et al. A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers. Ann Oncol 2010; [Epub ahead of print].
14. Lordick F., Luber B., Lorenzen S., et al. Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Br J Cancer 2010, 102:500-505.
15. Han S.W., Oh D.Y., Im S.A., et al. Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer. Br J Cancer 2009, 100:298-304.
16. Kim C, Lee JL, Ryu MH, et al. A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer. Invest New Drugs 2009; [Epub ahead of print].
17. Park S.R., Kook M.C., Choi I.J., et al. Predictive factors for the efficacy of cetuximab plus chemotherapy as salvage therapy in metastatic gastric cancer patients. Cancer Chemother Pharmacol 2010, 65:579-587.
18. Pinto C., Di Fabio F., Barone C., et al. Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study). Br J Cancer 2009, 101:1261-1268.
19. Pinto C., Di Fabio F., Siena S., et al. Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol 2007, 18:510-517.
20. Kanzler S., Trarbach T., Seufferlein T., et al. Cetuximab with irinotecan/folinic acid/5-FU as first-line treatment in advanced gastric cancer: A nonrandomized multicenter AIO phase II study. J Clin Oncol 2009, 27:4534. [abstract].
21. Woell E., Greil R., Eisterer W., et al. Oxaliplatin, irinotecan, cetuximab in advanced gastric cancer. First efficacy results of a multicenter phase II trial (AGMT Gastric-2) of the arbeitsgemeinschaft medikamentoese tumortherapie (AGMT). J Clin Oncol 2009, 27:4538. [abstract].
22. Zhang X, Xu J, Shen L, et al. A phase II study of cetuximab with cisplatin and capecitabine as first-line treatment in advanced gastric cancer. In: Proc GI ASCO 2009; LBA39 [abstract].
23. Yeh K., Hsu C., Hsu C., et al. Phase II study of cetuximab plus weekly cisplatin, 24-hour infusion of high-dose 5-fluorouracil, leucovorin for the first-line treatment of advanced gastric cancer. J Clin Oncol 2009, 27:4567. [abstract].
24. Ku G, Shah M, Tang L, et al. Cetuximab (C225) plus irinotecan/cisplatin (CPT/CDDP) for CPT/CDDP-refractory esophageal cancer. In: Proc GI ASCO 2008, vol. 54 [abstract].
25. Gold P., Goldman B., Iqbal S., et al. Cetuximab as second-line therapy in patients with metastatic esophageal cancer: a phase II southwest oncology group study. J Clin Oncol 2008, 26:4536. [abstract].
26. Tebbutt N, Sourjina T, Strickland A, et al. ATTAX2 - docetaxel plus cetuximab as second-line treatment for docetaxel refractory oesophago-gastric cancer: final results of a multi-center phase II trial by the AGITG. In: Proc GI ASCO 2008, vol. 87 [abstract].
27. Bjerregaard J, Schønnemann K, Jensen H, et al. Biweekly cetuximab and irinotecan as second-line therapy to patients with platinium-resistant gastroesophageal cancer. In: Proc GI ASCO 2009, vol. 73 [abstract].
28. Stein A, Al-Batran SE, Arnold D, Peinert S, Siewczynski R, Schmoll HJ. Cetuximab with irinotecan as salvage therapy in heavily pretreated patients with metastatic gastric cancer. In: Gastrointestinal Cancers Symposium 2007 [abstract 47].
29. Rao S, Starling N, Cunningham D, et al. Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study. Ann Oncol 2010; [Epub ahead of print].
30. Rao S., Starling N., Cunningham D., et al. Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer. Br J Cancer 2008, 99:868-874.
31. Cortés-Funes H., Rivera F., Alés I., et al. Phase II of trastuzumab and cisplatin in patients (pts) with advanced gastric cancer (AGC) with HER2/neu overexpression/amplification. J Clin Oncol 2007, 25:1-2. [abstract 4613].
32. Bekaii-Saab T.S., Roda J.M., Guenterberg K.D., et al. A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies. Mol Cancer Ther 2009, 8:2983-2991.
33. Van Cutsem E., Kang Y., Chung H., et al. Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy (CT) in firstline human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). J Clin Oncol 2009, 27:LBA4509. [abstract].
34. Iqbal S., Goldman B., Lenz H., Fenoglio-Preiser C., Blanke C. S0413: a phase II SWOG study of GW572016 (lapatinib) as first line therapy in patients (pts) with advanced or metastatic gastric cancer. J Clin Oncol 2007, 25:4621. [abstract].
35. Hecht J, Urba S, Koehler M, et al. Lapatinib monotherapy in recurrent upper gastrointestinal malignancy: phase II efficacy and biomarker analyses. In: Proc GI ASCO 2008, vol. 43 [abstract].
36. Galsky M., Von Hoff D., Neubauer M., et al. Target-specific, histologyindependent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors. J Clin Oncol 2009, 27:3541. [abstract].
37. Ocean AJ, Schnoll-Sussman F, Chen XE, et al. Recent results of phase II study of PS-341 (bortezomib) with or without irinotecan in patients (pts) with advanced gastric adenocarcinomas (AGA). In: Gastrointestinal Cancers Symposium. 2007 [abstract 45].
38. Shah MA, Power DG, Kindler HL, et al. A multicenter, phase II study of Bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma. Invest New Drugs 2010; [Epub ahead of print].
39. Jatoi A., Dakhil S.R., Foster N.R., et al. Bortezomib, paclitaxel, and carboplatin as a first-line regimen for patients with metastatic esophageal, gastric, and gastroesophageal cancer phase ii results from the north central cancer treatment group (N044B). J Thorac Oncol 2008, 3:516-520.
40. Schwartz G.K., Ilson D., Saltz L., et al. Phase II study of the cyclindependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma. J Clin Oncol 2001, 19:1985-1992.
41. Schwartz G.K., O'Reilly E., Ilson D., et al. Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors. J Clin Oncol 2002, 20:2157-2170.
42. Fornier M.N., Rathkopf D., Shah M., et al. Phase I dose-finding study of weekly docetaxel followed by flavopiridol for patients with advanced solid tumors. Clin Cancer Res 2007, 13:5841-5846.
43. Shah M.A., Kortmansky J., Gonen M., et al. A phase I study of weekly irinotecan (CPT), cisplatin (CIS), flavopiridol (F). J Clin Oncol 2004, 22. [abstract 4027].
44. Ajani J.A., Hecht R.J., Ho L., et al. An open-label, multinational, multicenter study of G17DT vaccination combined with cisplatin and 5-fluorouracil in patients with untreated, advanced gastric or gastroesophageal cancer: the GC4 study. Cancer 2006, 106:1908-1916.
45. Gilliam A.D., Watson S.A., Henwood M., et al. A phase II study of G17DT in gastric carcinoma. Eur J Surg Oncol 2004, 30:536-543.
46. Bang YJ, Kang YK, Kang WK, et al. Phase II study of sunitinib as second-line treatment for advanced gastric cancer. Invest New Drugs 2010; [Epub ahead of print].
47. Sun W., Powell M., O'Dwyer P.J., et al. Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. J Clin Oncol 2010, 28:2947-2951.
48. Dragovich T., McCoy S., Fenoglio-Preiser C.M., et al. Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol 2006, 24:4922-4927.
49. Doi T., Koizumi W., Siena S., et al. Efficacy, tolerability, pharmacokinetics of gefitinib (ZD1839) in pretreated patients with metastatic gastric cancer. J Clin Oncol 2003, 22. [abstract 1036].
50. Doi T., Muro K., Boku N., et al. Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer. J Clin Oncol 2010, 28:1904-1910.
51. Bramhall S.R., Hallissey M.T., Whiting J., et al. Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. Br J Cancer 2002, 86:1864-1870.
52. Jhawer M., Kindler H., Wainberg Z., et al. Assessment of two dosing schedules of GSK1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in metastatic gastric cancer (GC): interim results of a multicenter phase II study. J Clin Oncol 2009, 27:4502. [Abstract].
53. Ajani J.A., Jiang Y., Faust J., et al. A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma. Invest New Drugs 2006, 24:353-357.
54. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971, 285:1182-1186.
55. Kerbel R.S. Tumor angiogenesis. N Engl J Med 2008, 358:2039-2049.
56. Ferrara N., Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997, 18:4-25.
57. Gasparini G. Prognostic value of vascular endothelial growth factor in breast cancer. Oncologist 2000, 5(Suppl 1):37-44.
58. Eroglu A., Demirci S., Ayyildiz A., et al. Serum concentrations of vascular endothelial growth factor and nitrite as an estimate of in vivo nitric oxide in patients with gastric cancer. Br J Cancer 1999, 80:1630-1634.
59. Maeda K., Chung Y.S., Ogawa Y., et al. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 1996, 77:858-863.
60. Ferrara N., Hillan K.J., Gerber H.P., Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004, 3:391-400.
61. Presta L.G., Chen H., O'Connor S.J., et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997, 57:4593-4599.
62. Morabito A., DeMaio E., Di Maio M., Normanno N., Perrone F. Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. The Oncologist 2006, 11:753-754.
63. Abrams T.J., Lee L.B., Murray L.J., Pryer N.K., Cherrington J.M. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003, 2:471-478.
64. Mendel D.B., Laird A.D., Xin X., et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003, 9:327-337.
65. O'Farrell A.M., Abrams T.J., Yuen H.A., et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003, 101:3597-3605.
66. Ciardiello F., Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001, 7:2958-2970.
67. Tokunaga A., Onda M., Okuda T., et al. Clinical significance of epidermal growth factor (EGF), EGF receptor, and c-erbB-2 in human gastric cancer. Cancer 1995, 75:1418-1425.
68. Albanell J., Rojo F., Baselga J. Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD 1839. Semin Oncol 2001, 28(Suppl 16):56-66.
69. Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 2002, 20:1-13.
70. Takehana T., Kunitomo K., Suzuki S., et al. Expression of epidermal growth factor receptor in gastric carcinomas. Clin Gastroenterol Hepatol 2003, 1:438-445.
71. Burtness B., Goldwasser M.A., Flood W., et al. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 2005, 23:8646-8654.
72. Cunningham D., Humblet Y., Siena S., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004, 351:337-345.
73. Agarwala A., Hanna N., McCollum A., et al. Preoperative cetuximab, radiation (XRT) for patients (pts) with surgically resectable esophageal, gastroesophageal junction (GEJ) carcinomas: A pilot study from the Hoosier Oncology Group, the University of Texas Southwestern. J Clin Oncol 2009, 27:4557. [abstract].
74. Ma H, Ryan T, Newman E, et al. Neoadjuvant therapy of gastric cancer with irinotecan, cisplatin, and cetuximab followed by surgical resection and adjuvant chemoradiation. In: Proc GI ASCO 2009, vol. 58 [abstract].
75. Enzinger P., Yock T., Suh W., et al. Phase II cisplatin, irinotecan, cetuximab, concurrent radiation therapy followed by surgery for locally advanced esophageal cancer. J Clin Oncol 2006, 24:4064. [abstract].
76. Safran H., Suntharalingam M., Dipetrillo T., et al. Cetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicity. Int J Radiat Oncol Biol Phys 2008, 70:391-395.
77. Ruhstaller T., Pless M., Schuller J., et al. Cetuximab in combination with chemoradiotherapy prior to surgery in patients with resectable, locally advanced esophageal carcinoma: A prospective, multicenter phase lb-ll trial of the swiss group for clinical cancer research (SAKK 75/06). J Clin Oncol 2009, 27:4570. [abstract].
78. De Vita F., Orditura M., Innocente R., et al. Induction primary CT with Folfox-4, cetuximab followed by RT, cetuximab in locally advanced esophageal cancer (LAEC): analysis of preliminary data from B152 trial. J Clin Oncol 2008, 26:15524. [abstract].
79. Van Cutsem E., Peeters M., Siena S., et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007, 25:1658-1664.
80. Figlin R., Belldegrun A., Crawford J., et al. ABX-EGF a fully human antiepidermal growth factor receptor (EGFR) monoclonal antibody (mAb) in patients with advanced cancer: phase 1 clinical results. Proc Am Soc Clin Oncol 2002, 21:35. [abstract].
81. Herbst R.S., Fukuoka M., Baselga J. Gefitinib-a novel targeted approach to treating cancer. Nat Rev Cancer 2004, 4:956-965.
82. Fukuoka M., Yano S., Giaccone G., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) corrected. J Clin Oncol 2003, 21:2237-2246.
83. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353:123-132.
84. Moore M.J., Goldstein D., Hamm J., et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the national cancer institute of Canada clinical trials group. J Clin Oncol 2007, 25:1960-1966.
85. Meza-Junco J., Au H.J., Sawyer M.B. Trastuzumab for gastric cancer. Expert Opin Biol Ther 2009, 9:1543-1551.
86. Baselga J., Swain S.M. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 2009, 9:463-475.
87. Valabrega G., Montemurro F., Aglietta M. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol 2007, 18:977-984.
88. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005, 353:1659-1672.
89. Romond E.H., Perez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005, 353:1673-1684.
90. Smith I., Procter M., Gelber R.D., et al. 2-Year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomized controlled trial. Lancet 2007, 369:29-36.
91. Cobleigh M.A., Vogel C.L., Tripathy D., et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999, 17:2639-2648.
92. Vogel C.L., Cobleigh M.A., Tripathy D., et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002, 20:719-726.
93. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344:783-792.
94. Lackey K.L. Lessons from the drug discovery of lapatinib, a dual ErbB1/2 tyrosine kinase inhibitor. Curr Topics Med Chem 2006, 6:435-460.
95. Cameron D., Casey M., Press M., et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008, 112:533-543.
96. Geyer C.E., Forster J., Lindquist D., et al. Lapatinib plus capecitabine for HER2- positive advanced breast cancer. N Engl J Med 2006, 355:2733-2743.
97. Strimpakos A.S., Karapanagiotou E.M., Saif M.W., Syrigos K.N. The role of mTOR in the management of solid tumors: an overview. Cancer Treat Rev 2009, 35:148-159.
98. Lang S.A., Gaumann A., Koehl G.E., et al. Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model. Int J Cancer 2007, 120:1803-1810.
99. Jiang H., Agani F., Passaniti A., Semenza G.L. V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. Cancer Res 1997, 57:5328-5335.
100. Giorgetti-Peraldi Treins.S., Murdaca J., Semenza G.L., Van E. Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway. J Biol Chem 2002, 277:27975-27981.
101. Bjornsti M.A., Houghton P.J. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004, 4:335-348.
102. Motzer R.J., Escudier B., Oudard S., et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008, 372:449-456.
103. Fernández C.A., Yan L., Louis G., Yang J., Kutok J.L., Moses M.A. The matrix metalloproteinase-9/neutrophil gelatinase-associated lipocalin complex plays a role in breast tumor growth and is present in the urine of breast cancer patients. Clin Cancer Res 2005, 11:5390-5395.
104. Lochter A., Sternlicht M.D., Werb Z., Bissell M.J. The significance of matrix metalloproteinases during early stages of tumor progression. Ann N Y Acad Sci 1998, 857:180-193.
105. Giannelli G., Antonaci S. Gelatinases and their inhibitors in tumor metastasis: from biological research to medical applications. Histol Histopathol 2002, 17:339-345.
106. Nomura H., Sato H., Seiki M., Mai M., Okada Y. Expression of membrane-type matrix metalloproteinase in human gastric carcinomas. Cancer Res 1995, 55:3263-3266.
107. Monig S.P., Baldus S.E., Hennecken J.K., et al. Expression of MMP-2 is associated with progression and lymph node metastasis of gastric carcinoma. Histopathology 2001, 39:597-602.
108. Tierney G.M., Griffin N.R., Stuart R.C., et al. A pilot study of the safety and effects of the matrix metalloproteinase inhibitor marimastat in gastric cancer. Eur J Cancer 1999, 35:563-568.
109. Rao R.N. Targets for cancer therapy in the cell cycle pathway. Curr Opin Oncol 1996, 8:516-524.
110. Thomas J.P., Tutsch K.D., Cleary J.F., et al. Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol. Cancer Chemother Pharmacol 2002, 50:465-472.
111. Maik R.G., Kattice S.L., Bhat S.V., Alreja B., de Souza N.J., Rupp R.H. An anti-inflammatory cum immunomodulatory piperidinylbenzopyranone from Dysoxylum binectariferum: isolation, structure and total synthesis. Tetrahedron 1998, 44:2081-2086.
112. Wang W.H., Huang J.Q., Zheng G.F., et al. Non-steroidal anti-inflammatory drug use and the risk of gastric cancer: a systematic review and meta-analysis. J Natl Cancer Inst 2003, 95:1784-1791.
113. Govindan R., McLeod H., Mantravadi P., et al. Cisplatin, fluorouracil, celecoxib, and RT in resectable esophageal cancer: preliminary results. Oncology (Williston Park) 2004, 18:18-21.
114. Dawson S.J., Michael M., Biagi J., et al. A phase I/II trial of celecoxib with chemotherapy and radiotherapy in the treatment of patients with locally advanced oesophageal cancer. Invest New Drugs 2007, 25:123-129.
115. Enzinger P, Mamon H, Choi N, et al., Phase II cisplatin, irinotecan, celecoxib and concurrent radiation therapy followed by surgery for locally advanced esophageal cancer. In: Proc GI ASCO 2004, vol. 35 [abstract].
116. Philip P.A., Harris A.L. Potential for protein kinase C inhibitors in cancer therapy. Cancer Treat Res 1995, 78:3-27.